Delivery Order SPE2DB22D9112-SPE2DB26FTKGA
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,084.36 by the Defense Logistics Agency (DLA) on August 4, 2025, for the supply of Actemra 400 mg/20 ml vials. This firm fixed-price delivery order is not associated with a set-aside designation and carries an ultimate completion date of August 25, 2025. The award represents a single line item delivery under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency valued at $9,273.12 for the supply of Actemra Actpen 162 mg/0.9 ml injection pens. The award, issued on May 12, 2025, with an ultimate completion date of June 3, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's significant Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth up to $4,385.04 to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business located in Park Ridge, Illinois. The contract, which has no set-aside designation, is for the delivery of 4564299269 - Actemra Actpen 162 mg/0.9 ml 0.9ml syringes. This delivery order is part of a larger indefinite delivery contract (SPE2DB24FYW67) between DMS Pharmaceutical Group and DLA, valued at up to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,084.36 by the Defense Logistics Agency on September 16, 2025, for the supply of Actemra 400 mg/20 ml vials. This firm fixed-price delivery order is set to conclude by October 7, 2025, and will be fulfilled from the contractor's Park Ridge, Illinois location. The award was issued without a set-aside designation, leveraging the company's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $5,313.27 by the Defense Logistics Agency (DLA) on August 19, 2025. The delivery order covers the supply of Actemra 400 mg/20 mL vials, a biologic medication used primarily for treating rheumatoid arthritis and other inflammatory conditions. This award was issued without a set-aside designation and is scheduled for...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $9,273.12 to DMS Pharmaceutical Group Inc. for the supply of Actemra Actpen 162 mg/0.9 ml injections. The contract, issued on June 4, 2025, with an ultimate completion date of June 26, 2025, represents a standard procurement action with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the delivery...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order against its indefinite delivery contract with the Defense Logistics Agency to provide Actemra Actpen 162 mg/0.9 ml prefilled syringes. The $5,776 delivery order has a completion date of January 9, 2024 and was awarded on December 15, 2023. DMS Pharmaceutical Group will supply the pharmaceutical items to DLA Troop Support Medical facilities from its location in Park Ridge, Illinois. As a woman-owned small business,...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order against its indefinite delivery contract with the Defense Logistics Agency to provide Actemra Actpen 162 mg/0.9 ml prefilled syringes. The $5,776 delivery order has a completion date of November 28, 2023 and was awarded on November 3, 2023. DMS Pharmaceutical Group will supply the pharmaceutical items to DLA Troop Support Medical facilities from its location in Park Ridge, Illinois. As a woman-owned small...
- The U.S. Defense Logistics Agency has awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Actemra Actpen 162 mg/0.9 ml medication. The contract, valued at $6,577.56, has a completion date of February 21, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois and holds a larger indefinite delivery contract with DLA valued up to $4,999,999 through 2025 for a broad range of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $2,318.25 by the Defense Logistics Agency (DLA) on May 2, 2025. The contract, which carries no set-aside designation, calls for delivery of Actemra 162 mg/0.9 ml syringes with an ultimate completion date of May 23, 2025. Actemra (tocilizumab) is a biologic immunosuppressant used primarily to treat rheumatoid arthritis and...
- SPE2DB22D9112Indefinite Delivery Contract
- SPE2DB22D9112-SPE2DB26FTKGADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,685.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Actemra Actpen 162 mg/0.9 mL prefilled syringes. The award, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes the issuance of delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated performance across diverse product categories ranging from oncology treatments and biologics to routine medications and specialty pharmaceuticals. The company's PPV-G GEN V contract, designated SPE2DR with a $500 million ceiling and completion date of December 31, 2036, positions it as a regional prime vendor contractor supporting military healthcare facilities globally. The current delivery order for Actemra, a biologic immunosuppressant used in rheumatoid arthritis treatment, reflects the contractor's ongoing role in fulfilling specialized pharmaceutical requirements for the Department of Defense medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 10/16/25 |